Rheumatoid arthritis (RA) with concomitant hepatitis B virus (HBV) infection represents a therapeutic challenge due to the risk of HBV reactivation under immunosuppressive treatment. To date there are few data concerning the HBV reactivation following treatment with abatacept coming from anecdotal case reports. This observational retrospective study was aimed to assess the safety profile of abatacept in this particular clinical setting.
|Titolo:||Safety of abatacept in rheumatoid arthritis with serological evidence of past or present hepatitis B virus infection|
|Data di pubblicazione:||2016|
|Appare nelle tipologie:||03.1 Articolo su rivista|